Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01738139 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab and Imatinib Mesylate in Advanced Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT01738139: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01738139 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01738139, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ipilimumab and imatinib mesylate in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ipilimumab and imatinib mesylate may work better in treating patients with solid tumors.
Interventions
- BIOLOGICAL Ipilimumab
- DRUG Imatinib Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2013-02-19 |
| Est. Completion | 2023-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01738139
The ClinicalTrials.gov registry entry for NCT01738139 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01738139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01738139 about?
NCT01738139 is a clinical study titled "Ipilimumab and Imatinib Mesylate in Advanced Cancer". This phase I trial studies the side effects and best dose of ipilimumab and imatinib mesylate in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune ...
What is the current status of trial NCT01738139?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2013-02-19. Estimated completion is 2023-12-13.
What interventions are being tested in trial NCT01738139?
The interventions under investigation include: Ipilimumab (BIOLOGICAL), Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT01738139?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.